A Revised Estimate of the Burden of Illness of Gout()

Por Wertheimer, Albert, Morlock, Robert, Becker, Michael A.
Publicado em 2013

Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

Por Terkeltaub, Robert, Bushinsky, David A, Becker, Michael A
Publicado em 2006

Evidence for X-linkage of human phosphoribosylpyrophosphate synthetase

Por Yen, Richard C. K., Adams, William B., Lazar, Cheri, Becker, Michael A.
Publicado em 1978

Human Phosphoribosylpyrophosphate Synthetase: Increased Enzyme Specific Activity in a Family with Gout and Excessive Purine Synthesis

Por Becker, Michael A., Kostel, Paul J., Meyer, Laurence J., Seegmiller, J. Edwin
Publicado em 1973

Purine Metabolism in Normal and Thioguanine-Resistant Neuroblastoma

Por Wood, Alexander W., Becker, Michael A., Minna, John D., Seegmiller, J. Edwin
Publicado em 1973

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy

Por Baraf, Herbert S. B., Yood, Robert A., Ottery, Faith D., Sundy, John S., Becker, Michael A.
Publicado no J Clin Rheumatol (2014)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

Por Lipsky, Peter E, Calabrese, Leonard H, Kavanaugh, Arthur, Sundy, John S, Wright, David, Wolfson, Marsha, Becker, Michael A
Publicado em 2014

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Por Becker, Michael A, Schumacher, H Ralph, Espinoza, Luis R, Wells, Alvin F, MacDonald, Patricia, Lloyd, Eric, Lademacher, Christopher
Publicado em 2010

Long-term safety of pegloticase in chronic gout refractory to conventional treatment

Por Becker, Michael A, Baraf, Herbert S B, Yood, Robert A, Dillon, Aileen, Vázquez-Mellado, Janitzia, Ottery, Faith D, Khanna, Dinesh, Sundy, John S
Publicado em 2013

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Por Baraf, Herbert SB, Becker, Michael A, Gutierrez-Urena, Sergio R, Treadwell, Edward L, Vazquez-Mellado, Janitzia, Rehrig, Claudia D, Ottery, Faith D, Sundy, John S, Yood, Robert A
Publicado em 2013

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?

Por STAMP, LISA K., KHANNA, PUJA P., DALBETH, NICOLA, BOERS, MAARTEN, MAKSYMOWYCH, WALTER P., SCHUMACHER, H. RALPH, BECKER, MICHAEL A., MacDONALD, PATRICIA A., EDWARDS, N. LAWRENCE, SINGH, JASVINDER A., SIMON, LEE S., McQUEEN, FIONA M., NEOGI, TUHINA, GAFFO, ANGELO L., STRAND, VIBEKE, TAYLOR, WILLIAM J.
Publicado em 2011

Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10

Por SINGH, JASVINDER A., TAYLOR, WILL J., SIMON, LEE S., KHANNA, PUJA P., STAMP, LISA K., McQUEEN, FIONA M., NEOGI, TUHINA, GAFFO, ANGELO L., BECKER, MICHAEL A., MacDONALD, PATRICIA A., DABBOUS, OMAR, STRAND, VIBEKE, DALBETH, NICOLA D., ALETAHA, DANIEL, EDWARDS, N. LAWRENCE, SCHUMACHER, H. RALPH
Publicado em 2011